Ordinary Reweighting | RBC Biotech Opportunities Index Series 2 | Effective Date 3rd July 2023
In the ordinary reweighting, the following index composition will be implemented effective open 03.07.2023:
ABBVIE INC |
AGIOS PHARMACEUTICALS INC |
ALNYLAM PHARMACEUTICALS INC |
AMGEN INC |
BIOGEN INC |
ELI LILLY & CO |
GILEAD SCIENCES INC |
INCYTE CORP |
INTRA-CELLULAR THERAPIES INC |
KARUNA THERAPEUTICS INC |
PACIRA BIOSCIENCES INC |
SAREPTA THERAPEUTICS INC |
SEAGEN INC |
XENON PHARMACEUTICALS INC |